Iterum Therapeutics (NASDAQ:NRBO) posted its quarterly earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.20), MarketWatch Earnings reports.
NASDAQ NRBO opened at $13.74 on Friday. The stock has a 50 day simple moving average of $16.04. Iterum Therapeutics has a 12 month low of $5.95 and a 12 month high of $36.22. The company has a market cap of $222.92 million, a P/E ratio of -3.37 and a beta of 0.85.
A number of research firms have issued reports on NRBO. ValuEngine lowered shares of Iterum Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 7th. LADENBURG THALM/SH SH began coverage on shares of Iterum Therapeutics in a research note on Tuesday, February 18th. They set a “buy” rating for the company. Finally, Zacks Investment Research lowered shares of Iterum Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st.
NeuroBo Pharmaceuticals, Inc provides novel therapies for diabetic neuropathic pain and central nervous system diseases. NeuroBo Pharmaceuticals, Inc was founded in 2017 and is based in Boston, Massachusetts.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.